Kyprolis Study in Newly Diagnosed Disease Doesn’t Meet Primary Endpoint—PFS October 20, 2016Vol.39 No.09
Novartis’s LEE011 + Letrozole Shows Superior PFS as First-Line Treatment for HR+/HER2- Advanced Breast Cancer October 20, 2016Vol.39 No.09
Phase III Trial Confirms ORR in Previously Treated Patients who Received Opdivo October 20, 2016Vol.39 No.09
Yervoy Improved OS in Fully Resected Stage III Patients from Phase III Study October 20, 2016Vol.39 No.09
Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status October 20, 2016Vol.39 No.09
Conversation with The Cancer Letter Davidson Moves to Seattle Cancer Consortium October 14, 2016Vol.42 No.38By Paul Goldberg
